OR5K1 Antibody

What is OR5K1 and why is it significant for olfactory research?

OR5K1 (Olfactory Receptor Family 5 Subfamily K Member 1) is a G protein-coupled receptor (GPCR) belonging to the largest subfamily of class A GPCRs. As one of approximately 400 odorant receptor genes in humans, OR5K1 plays a crucial role in olfactory signal transduction. Its significance stems from its recent comprehensive characterization in terms of cognate agonists, making it a valuable model for understanding odorant-receptor interactions. The receptor has been identified by multiple synonyms in the literature, including HTPCRX10 and Olfactory receptor OR3-8 . Research on OR5K1 contributes to our broader understanding of the molecular mechanisms underlying olfaction and GPCR function.

What experimental applications are supported by commercially available OR5K1 antibodies?

Commercial OR5K1 antibodies, such as the rabbit polyclonal antibody (A100884), are validated for Western Blot (WB) and ELISA applications . These antibodies enable researchers to detect the 36kDa OR5K1 protein in human samples, particularly using recommended dilutions of 1:500-1:1000 for WB and 1:10000 for ELISA . Validation data typically demonstrates successful detection in human cell lysates (e.g., HeLa cells), confirming antibody functionality in standard laboratory conditions. While these core applications are well-established, researchers should conduct their own validation for novel applications or cell types not covered in product literature.

What is the optimal sample preparation protocol for OR5K1 detection in Western blotting?

For optimal OR5K1 detection in Western blotting, samples should be prepared with particular attention to membrane protein solubilization. Begin with cell lysis in a buffer containing 1% Triton X-100 or similar non-ionic detergent, supplemented with protease inhibitors to prevent degradation. After sonication and centrifugation (12,000g for 15 minutes at 4°C), collect the supernatant and determine protein concentration. Load 20-50μg of total protein per lane on SDS-PAGE gels. For transfer, PVDF membranes often yield better results than nitrocellulose for hydrophobic GPCRs like OR5K1. Block with 5% non-fat milk in TBST for 1 hour at room temperature. Apply the primary OR5K1 antibody at 1:500-1:1000 dilution overnight at 4°C . After washing, incubate with HRP-conjugated secondary antibody (anti-rabbit IgG) and develop using enhanced chemiluminescence. This protocol has been validated with HeLa cell lysates as demonstrated in available scientific validation data .

What ligands are known to activate OR5K1 and how are they characterized?

OR5K1 is activated by several pyrazine derivatives, with 2,3-diethyl-5-methylpyrazine (EC50 = 10.29 μM) being the most potent agonist identified to date . Another significant agonist is 2-ethyl-3,6-dimethylpyrazine with an EC50 of 14.85 μM . Research has established that the activity of OR5K1 molecules relies on the presence and position of aliphatic chains, as the pyrazine moiety alone does not activate this receptor . Notably, when testing individual isomers from a mixture of 2-ethyl-3,5(6)-dimethylpyrazine, researchers found differential activation: 2-ethyl-3,6-dimethylpyrazine activated the receptor effectively, while 2-ethyl-3,5-dimethylpyrazine could not reach saturation within the tested concentration range . This structure-activity relationship provides critical insights into the binding preferences of OR5K1 and guides rational design of other potential ligands.

What are the key structural features of OR5K1's orthosteric binding site?

The orthosteric binding site of OR5K1 contains several key residues that determine ligand specificity and receptor activation. Two leucine residues, L104^3.32 and L255^6.51, have been experimentally identified as critical for agonist binding . Mutation of these residues to alanine shifts the EC50 values significantly: for the potent agonist 2,3-diethyl-5-methylpyrazine, the EC50 increases from 10.29 μM in wild-type to 525.28 ± 92.28 μM for L104^3.32A and 478.36 ± 185.10 μM for L255^6.51A mutants . These leucines are conserved in 10.6% and 15.5% of human ORs respectively, and are highly conserved (96-98%) in OR5K1 orthologs across species . They form part of a set of 22 amino acids that constitute a generalized odorant binding pocket in ORs. Interestingly, while F202^5.42 and F256^6.52 point toward the binding site in some structural models, experimental data confirms they do not significantly affect OR5K1 activation .

How do computational models of OR5K1 compare with experimental findings?

Computational modeling of OR5K1 has been approached through both AI-driven methods (using AlphaFold) and traditional homology modeling, with interesting divergences between the approaches . A key difference was observed in the extracellular loop 2 (ECL2) structure: homology models displayed an antiparallel β-sheet, while AlphaFold predicted a β-strand forming a sheet with the N-terminus and ending with a small α-helix inside the orthosteric binding site . When compared against known GPCR structural patterns, the homology model ECL2 aligned with established folds (cluster B), while the AlphaFold prediction created a novel structural pattern . Notably, recent preprint data on the CryoEM structure of another odorant receptor (OR51E2) shows ECL2 folding similar to AlphaFold predictions for OR5K1 . Induced-fit docking simulations were used to refine these models, resulting in structures that better rationalize the differential activity of agonists versus inactive molecules . This iterative refinement process demonstrates how computational approaches can be guided by and aligned with experimental mutagenesis data.

What techniques are most effective for studying OR5K1 ligand interactions?

For studying OR5K1 ligand interactions, a multi-modal approach yields the most comprehensive results. Calcium imaging assays in heterologous expression systems (typically HEK293T cells co-expressing OR5K1 and Gα15/16) provide functional readouts of receptor activation by measuring intracellular calcium flux upon ligand binding . Dose-response curves with multiple concentrations (typically 3-300 μM) of test compounds enable accurate EC50 determination. For molecular-level insights, site-directed mutagenesis of key residues like L104^3.32 and L255^6.51, followed by functional testing of mutants, reveals specific ligand-receptor interactions . Computational approaches, including induced-fit docking (IFD) simulations, help visualize binding modes and predict activity of novel compounds. The most successful research strategies combine these approaches: experimental identification of active compounds, mutagenesis studies to identify key residues, and computational modeling guided by experimental data to refine structural understanding .

What are the recommended protocols for validating OR5K1 antibody specificity?

A comprehensive validation protocol for OR5K1 antibody specificity should include multiple complementary approaches. Begin with Western blot analysis using positive control lysates (such as HeLa cells) which express endogenous OR5K1 . Compare these results with negative controls using cells known to have minimal OR5K1 expression. For definitive validation, perform knockout/knockdown controls: compare antibody reactivity in OR5K1 siRNA-treated cells versus scrambled siRNA controls. Peptide competition assays provide another layer of validation—pre-incubate the antibody with excess immunizing peptide (derived from human OR5K1 amino acids 46-95) before immunoblotting; specific signals should be blocked . For overexpressed systems, compare detection in cells transfected with OR5K1 expression vectors versus empty vector controls. Finally, verify the antibody detects the expected 36kDa band , with appropriate controls for post-translational modifications that might alter molecular weight. Document all validation experiments with appropriate loading controls and molecular weight markers.

How can researchers overcome challenges in detecting membrane-localized OR5K1?

Detecting membrane-localized OR5K1 presents several challenges due to its hydrophobic nature, potential low expression levels, and complex tertiary structure. To overcome these obstacles, researchers should consider the following methodological approaches: (1) For immunocytochemistry or immunohistochemistry, optimize fixation conditions—try 4% paraformaldehyde for 10-15 minutes or methanol/acetone mixtures, as different fixatives can significantly impact epitope accessibility; (2) Incorporate antigen retrieval steps, such as citrate buffer treatment (pH 6.0) at 95°C for 20 minutes for FFPE samples; (3) For Western blotting, use specialized membrane protein extraction kits containing multiple detergents (combinations of Triton X-100, CHAPS, and digitonin often yield better results than single detergents); (4) Consider using cell surface biotinylation followed by streptavidin pull-down to enrich for plasma membrane proteins before immunoblotting; (5) For low-abundance receptors, implement signal amplification systems like tyramide signal amplification; (6) When possible, use fresh rather than frozen tissues, as membrane proteins can be particularly susceptible to freeze-thaw degradation. These methodological adjustments often need to be empirically optimized for each experimental system.

How do OR5K1 single nucleotide variations affect ligand binding and antibody recognition?

Single nucleotide variations (SNVs) in OR5K1 can significantly impact both ligand binding properties and antibody recognition patterns. Two notable missense variations have been reported in human OR5K1: L104^3.32I (rs777947557) and L255^6.51F (rs1032366530), both occurring at frequencies below 0.01 in the population . These substitutions affect residues experimentally confirmed to be critical for agonist binding. While the L104^3.32I variation represents a conservative change that also occurs naturally in the OR5K1 ortholog of Aotus nancymaae (New World monkey), the L255^6.51F variation introduces a more substantial change from an aliphatic to an aromatic residue . Researchers should consider these variations when interpreting heterogeneous responses across different human samples. From an antibody perspective, if the immunizing peptide (amino acids 46-95) encompasses any variable regions, antibody recognition could be compromised in samples with SNVs. When studying populations with known OR5K1 polymorphisms, researchers should consider genotyping samples and potentially developing variant-specific antibodies for comprehensive detection.

What are the recommended approaches for comparative analysis of OR5K1 with related olfactory receptors?

Comparative analysis of OR5K1 with related olfactory receptors requires a strategic multi-level approach. At the sequence level, construct phylogenetic trees using specialized GPCR-specific alignment algorithms that account for the conserved seven-transmembrane architecture. Focus particularly on the variability within binding pocket residues—OR5K1's binding pocket includes the critical L104^3.32 and L255^6.51 residues that are conserved in only 10.6% and 15.5% of human ORs respectively . At the functional level, implement parallel screening of multiple receptors against the same ligand libraries, particularly focusing on pyrazine derivatives with varying aliphatic substitutions that show differential activity on OR5K1 . For structural comparisons, utilize the emerging AI-driven models together with homology models, with special attention to the diverse ECL2 conformations that distinguish different receptor subfamilies . When performing immunological detection of multiple ORs, carefully select antibodies raised against divergent regions to minimize cross-reactivity, and always validate with receptor-specific overexpression systems. This comprehensive approach enables meaningful insights into the evolutionary and functional relationships between OR5K1 and its structural homologs.

What experimental approaches can determine if the OR5K1 antibody affects receptor function?

To determine whether an OR5K1 antibody affects receptor function, researchers should implement a systematic series of functional assays comparing receptor activity in the presence and absence of the antibody. Begin with calcium imaging assays in heterologous expression systems (HEK293T cells expressing OR5K1): challenge cells with known agonists like 2,3-diethyl-5-methylpyrazine after pre-incubation with varying concentrations of the OR5K1 antibody (typically 1-10 μg/mL). Compare EC50 values and maximum response amplitudes between antibody-treated and control conditions. Next, perform live-cell immunostaining to determine if the antibody causes receptor internalization or redistribution away from the plasma membrane. For more detailed mechanistic insights, implement BRET (Bioluminescence Resonance Energy Transfer) or FRET assays with tagged G-proteins to assess if antibody binding alters G-protein coupling efficiency. Additionally, compare antibody effects on wild-type receptors versus mutants (particularly L104^3.32A and L255^6.51A) to determine if antibody binding and functional effects involve these critical residues. Finally, epitope mapping using peptide arrays can identify precisely which receptor regions interact with the antibody, enabling prediction of potential functional consequences.

What strategies can resolve non-specific binding issues with OR5K1 antibodies?

Non-specific binding issues with OR5K1 antibodies can be systematically addressed through several optimization strategies. First, increase blocking stringency by using 5% BSA instead of milk (particularly important for phospho-specific detection), and extend blocking time to 2 hours at room temperature. Second, optimize antibody concentration—perform titration experiments starting from the recommended 1:500-1:1000 dilution and adjust based on signal-to-noise ratio. Third, modify wash procedures by increasing the number of washes (minimum 5 times for 5 minutes each) and adding low concentrations (0.1-0.3%) of Triton X-100 to washing buffers. Fourth, consider alternative secondary antibodies; test products from different manufacturers as some may produce lower background with your specific samples. Fifth, pre-adsorb the antibody with tissues or cell lysates lacking OR5K1 expression to remove antibodies that bind to common epitopes. Sixth, for tissue sections, include an avidin/biotin blocking step if using biotin-based detection systems. Finally, validate that your observed non-specific bands differ from the expected 36kDa OR5K1 signal , and document their molecular weights to help distinguish them from target signals in future experiments.

How can researchers optimize storage conditions for maintaining OR5K1 antibody activity?

Optimal storage of OR5K1 antibodies requires careful attention to conditions that preserve protein structure and function. Upon receipt, aliquot the antibody into single-use volumes (typically 10-20 μL) in sterile microcentrifuge tubes to minimize freeze-thaw cycles, which are particularly damaging to antibody activity. Store these aliquots at -20°C as recommended by manufacturers , preferably in a non-frost-free freezer to avoid temperature fluctuations. For working solutions, maintain at 4°C and use within 1-2 weeks, adding sodium azide (0.02%) as a preservative for longer-term refrigerated storage . Avoid diluting stock antibody in buffers containing detergents or reducing agents unless immediately using the preparation. When handling, always wear gloves and use clean pipette tips to prevent contamination. Monitor antibody performance over time by periodically testing aliquots against positive control samples, documenting signal intensity and background levels. If diminished activity is observed after prolonged storage, consider using signal enhancement methods or purchasing a new lot. Finally, maintain detailed records of storage conditions, freeze-thaw cycles, and performance to establish optimal handling protocols for your specific research applications.

What technical considerations apply when comparing data from different OR5K1 antibody sources?

When comparing data generated using different OR5K1 antibody sources, researchers must consider several technical variables that could influence results interpretation. First, examine the immunogen differences—antibodies raised against different epitopes (regions of the OR5K1 protein) may have distinct binding characteristics; confirm whether they target the same region (e.g., amino acids 46-95) or different segments. Second, assess host species and antibody format (polyclonal versus monoclonal)—polyclonal antibodies like the rabbit anti-OR5K1 recognize multiple epitopes, potentially offering higher sensitivity but variable specificity compared to monoclonals. Third, validate each antibody independently using the same positive control samples and identical protocols before comparative studies. Fourth, consider cross-reactivity profiles, particularly with closely related olfactory receptors; comprehensive validation should include testing against OR5K2 and other sequence-similar receptors. Fifth, implement ratiometric approaches when possible, normalizing OR5K1 signals to invariant controls processed identically across antibody conditions. Sixth, when publishing comparative data, clearly document antibody catalog numbers, lot numbers, dilutions, incubation conditions, and detection methods to enable proper interpretation and reproducibility. These considerations are essential for distinguishing true biological variations from method-dependent artifacts.

Table 1: Comparative Properties of Key OR5K1 Agonists

*Could not be measured to saturation with the available concentration range .